Table 1.
Baseline characteristics according to treatment group (n = 40)
| Placebo n = 16 | 1 g n3‐PUFA n = 12 | 4 g n3‐PUFA n = 12 | |
|---|---|---|---|
| Age, years | 56 (46‐63) | 59 (54‐63) | 64 (58‐66) |
| Female, %(n) | 25 (4) | 17 (2) | / |
| Aetiology %(n) | |||
| Hypertension | 69 (11) | 67 (8) | 50 (6) |
| Myocarditis | 6 (1) | 8 (1) | 25 (3) |
| Valvular disease | / | / | 8 (1) |
| Alcohol | 13 (2) | / | 8 (1) |
| Other | 13 (2) | 25 (3) | 8 (1) |
| NYHA III, %(n) | 94 (15) | 83 (10) | 92 (11) |
| LVEF, % | 25 (19‐30) | 25 (22‐33) | 27 (19‐29) |
| NT‐proBNP, pg/mL | 2950 (2187‐4525) | 3017 (2269‐5306) | 3149 (2586‐4891) |
| BMI, kg/m2 | 27 (24‐31) | 26 (25‐28) | 28 (26‐30) |
| CRT, %(n) | 25 (4) | 33 (4) | 25 (3) |
| Beta blocker, %(n) | 100 (16) | 100 (12) | 100 (12) |
| ACEi/ARB, %(n) | 100 (16) | 100 (12) | 100 (12) |
| MRA, %(n) | 63 (10) | 75 (9) | 91 (11) |
| Statin, %(n) | 25 (4) | 25 (3) | 25 (3) |
| Hyperlipidemia, %(n) | 38 (6) | 33 (4) | 42 (5) |
| Diabetes, %(n) | 13 (2) | 17 (2) | 33 (4) |
| Systolic BP, mm Hg | 105 (102‐115) | 104 (97‐113) | 112 (104‐120) |
| Haemoglobin, g/dL | 12.9 (12.2‐13.6) | 13.4 (12.4‐13.8) | 14.1 (12.6‐14.7) |
| eGFR, mL/min/1.73 m2 | 70 (59‐87) | 62 (40‐82) | 77 (54‐97) |
| Triglycerides, mg/dL | 130 (96‐168) | 157 (99‐190) | 103 (78‐156) |
| Total cholesterol, mg/dL | 167 (153‐196) | 160 (141‐182) | 161 (156‐214) |
| LDL, mg/dL | 103 (93‐111) | 83 (74‐113) | 95 (88‐117) |
| HDL, mg/dL | 42 (32‐55) | 45 (32 ‐51) | 37 (33‐49) |
| AST, U/L | 25 (22‐34) | 24 (19‐29) | 27 (24‐31) |
| ALT, U/L | 27 (23‐33) | 19 (18‐22) | 25 (19‐34) |
| Fibrinogen, mg/dL | 424 (359‐502) | 416 (367‐493) | 372 (337‐441) |
| Leukocytes, G/L | 6.1 (5.5‐6.5) | 6.6 (5.6‐8) | 7.6 (6.7‐9.3) |
| CRP, mg/dL | 0.46 (0.18‐1.32) | 0.49 (0.27‐0.83) | 0.62 (0.27‐1.58) |
| HDL Inflammatory Index | 0.70 (0.63‐0.97) | 0.55 (0.53‐0.77) | 0.63 (0.55‐0.78) |
Counts are given as numbers and percentages. Continuous variables are given as median (interquartile range (IQR)).
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CRP, c‐reactive protein; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate calculated using Cockcroft‐Gault formula; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; NYHA, New York heart association class; PUFA, polyunsaturated fatty acids.